Evaluation of quality of life in patients with oral cancer after mandibular resection: Comparing no reconstruction, reconstruction with plate, and reconstruction with flap.

This cross-sectional study aimed to assess and compare quality of life in patients with advanced oral cavity tumors after mandibular resection in 3 groups (no reconstruction, reconstruction with plate, and reconstruction with flap) at the Cancer Institute, affiliated to Tehran University of Medical Sciences.

Quality of life was measured using the EuropeanOrganization for Research and Treatment of Cancer core quality of life questionnaire and EuropeanOrganization for Research and Treatment of Cancer head and neck cancer-specific quality of life questionnaire-35 items.

The comparison was tested using Kurskal-Wallis analysis. All 120 patients were entered into the study. The mean age of patients was 48.5 (standard deviation = 18.1) years. Patients presented with advanced stage of the disease and underwent mandibular resection with no reconstruction (n = 40), reconstruction with plate (n = 41), and reconstruction with flap (n = 39).

The findings showed that in general, there were no statistically significant differences in quality of life among 3 groups except for speech problem (P = .4), dry mouth (P = .03), and feeling ill (P = .04).

SC-PEG-SC

abx085129-08kDa1g 0.8 kDa; 1 g
EUR 328
  • Shipped within 5-10 working days.

SC-PEG-SC

abx085129-10kDa1g 10 kDa; 1 g
EUR 328
  • Shipped within 5-10 working days.

SC-PEG-SC

abx085129-20kDa1g 20 kDa; 1 g
EUR 328
  • Shipped within 5-10 working days.

SC-PEG-SC,10K

33-HO023023-10K
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,1K

33-HO023023-1K
  • EUR 143.00
  • EUR 329.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,20K

33-HO023023-20K
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,2K

33-HO023023-2K
  • EUR 143.00
  • EUR 329.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,3.4K

33-HO023023-3.4K
  • EUR 143.00
  • EUR 329.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,400

33-HO023023-400
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,4K

33-HO023023-4K
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,500

33-HO023023-500
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,5K

33-HO023023-5K
  • EUR 143.00
  • EUR 329.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,600

33-HO023023-600
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,6K

33-HO023023-6K
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC-PEG-SC,800

33-HO023023-800
  • EUR 167.00
  • EUR 399.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

SC 79

B5663-10 10 mg
EUR 148
Description: IC50: N/ASC 79 is an activator of Akt. Akt/PKB with anti-apoptotic activity (a serine/threonine protein kinase) is one of the major downstream targets of PtdIns P3 signaling pathway.

SC 79

B5663-50 50 mg
EUR 334
Description: IC50: N/ASC 79 is an activator of Akt. Akt/PKB with anti-apoptotic activity (a serine/threonine protein kinase) is one of the major downstream targets of PtdIns P3 signaling pathway.

SC-10

B6299-10 10 mg
EUR 213

SC-10

B6299-50 50 mg
EUR 744

SC-9

B6302-10 10 mg
EUR 284

SC 19220

B6633-10 10 mg
EUR 216

SC 19220

B6633-25 25 mg
EUR 415

SC 19220

B6633-5 5 mg
EUR 144

SC 560

B6786-10 10 mg
EUR 177
Description: IC50: 0.009 ?M for COX-1; 6.3 ?M for COX-2SC-560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trif luoromethylpyrazole] is a COX-1-selective inhibitor, which can be used as a pharmacological tool to study the role of COX-1-derived PGs in inflammation and pain.

SC 560

B6786-25 25 mg
EUR 328
Description: IC50: 0.009 ?M for COX-1; 6.3 ?M for COX-2SC-560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trif luoromethylpyrazole] is a COX-1-selective inhibitor, which can be used as a pharmacological tool to study the role of COX-1-derived PGs in inflammation and pain.

SC 560

B6786-5 5 mg
EUR 119
Description: IC50: 0.009 ?M for COX-1; 6.3 ?M for COX-2SC-560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trif luoromethylpyrazole] is a COX-1-selective inhibitor, which can be used as a pharmacological tool to study the role of COX-1-derived PGs in inflammation and pain.

SC 560

B6786-5.1 10 mM (in 1mL DMSO)
EUR 148
Description: IC50: 0.009 ?M for COX-1; 6.3 ?M for COX-2SC-560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trif luoromethylpyrazole] is a COX-1-selective inhibitor, which can be used as a pharmacological tool to study the role of COX-1-derived PGs in inflammation and pain.

SC-514

B1585-10 10 mg
EUR 108
Description: SC-514 is a cell-permeable and selective inhibitor of IKK-2 with IC50 value of 3-12?M [1, 2].SC-514 inhibits all forms of recombinant human IKK-2 with IC50 values in the 3?12?M range. It also inhibits the native IKK complex.

SC-514

B1585-5.1 10 mM (in 1mL DMSO)
EUR 125
Description: SC-514 is a cell-permeable and selective inhibitor of IKK-2 with IC50 value of 3-12?M [1, 2].SC-514 inhibits all forms of recombinant human IKK-2 with IC50 values in the 3?12?M range. It also inhibits the native IKK complex.

SC-514

B1585-50 50 mg
EUR 270
Description: SC-514 is a cell-permeable and selective inhibitor of IKK-2 with IC50 value of 3-12?M [1, 2].SC-514 inhibits all forms of recombinant human IKK-2 with IC50 values in the 3?12?M range. It also inhibits the native IKK complex.

SC 51322

B5338-10 10 mg
EUR 216

SC 51322

B5338-25 25 mg
EUR 415

SC 51322

B5338-5 5 mg
EUR 144

SC 58125

B5347-10 10 mg
EUR 183

SC 58125

B5347-25 25 mg
EUR 342

SC 58125

B5347-5 5 mg
EUR 125

SC 66

B5575-10 10 mg
EUR 129

SC 66

B5575-100 100 mg
EUR 634

SC 66

B5575-25 25 mg
EUR 238

SC 51089

B7496-10 10 mg
EUR 229

SC 51089

B7496-25 25 mg
EUR 415

SC 51089

B7496-5 5 mg
EUR 144

SC 236

B7533-10 10 mg
EUR 224

SC 236

B7533-5 5 mg
EUR 154

SC 236

B7533-50 50 mg
EUR 833

SC 26196

B7608-10 10 mg
EUR 242

SC 26196

B7608-25 25 mg
EUR 485

SC 26196

B7608-5 5 mg
EUR 189

SC-52012

HY-19163 5mg
EUR 5560

SC-560

HY-59105 10mg
EUR 215

SC-514

HY-13802 10mM/1mL
EUR 141

SC-560

GK2799-50MG 50 mg
EUR 349

SC 514

20-abx076580
  • EUR 272.00
  • EUR 606.00
  • 10 mg
  • 50 mg
  • Shipped within 5-12 working days.

SC 79

20-abx076733
  • EUR 648.00
  • EUR 286.00
  • 25 mg
  • 5 mg
  • Shipped within 5-12 working days.

mPEG-SC

abx085126-075kDa1g 0.75 kDa; 1 g
EUR 328
  • Shipped within 5-10 working days.

mPEG-SC

abx085126-10kDa1g 10 kDa; 1 g
EUR 356
  • Shipped within 5-10 working days.

mPEG-SC

abx085126-1kDa1g 1 kDa; 1 g
EUR 356
  • Shipped within 5-10 working days.

mPEG-SC

abx085126-20kDa1g 20 kDa; 1 g
EUR 356
  • Shipped within 5-10 working days.

mPEG-SC

abx085126-2kDa1g 2 kDa; 1 g
EUR 398
  • Shipped within 5-10 working days.

Sc-514

abx188875-1g 1 g
EUR 871
  • Shipped within 1-2 weeks.

SC 57461A

A4408-10 10 mg
EUR 241
Description: SC-57461A is a selective inhibitor of human recombinant LTB4 with IC50 value of 49 nM [1].LTB4 (leukotriene B (4)) is a leukotriene and plays an important role in inflammation.

SC 57461A

A4408-25 25 mg
EUR 485
Description: SC-57461A is a selective inhibitor of human recombinant LTB4 with IC50 value of 49 nM [1].LTB4 (leukotriene B (4)) is a leukotriene and plays an important role in inflammation.

SC 57461A

A4408-5 5 mg
EUR 171
Description: SC-57461A is a selective inhibitor of human recombinant LTB4 with IC50 value of 49 nM [1].LTB4 (leukotriene B (4)) is a leukotriene and plays an important role in inflammation.

SC 144

A2173-25 25 mg
EUR 456
Description: SC144 is an inhibitor of gp130 with IC50 values of 0.43 ?mol/L and 0.88 ?mol/L in NCI/ADR-RES and HEY cell lines, respectively [1].SC144 is a ?rst-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer.

SC 144

A2173-5 5 mg
EUR 142
Description: SC144 is an inhibitor of gp130 with IC50 values of 0.43 ?mol/L and 0.88 ?mol/L in NCI/ADR-RES and HEY cell lines, respectively [1].SC144 is a ?rst-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer.

SC 144

A2173-5.1 10 mM (in 1mL DMSO)
EUR 151
Description: SC144 is an inhibitor of gp130 with IC50 values of 0.43 ?mol/L and 0.88 ?mol/L in NCI/ADR-RES and HEY cell lines, respectively [1].SC144 is a ?rst-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer.

SC-514

2442-25
EUR 370

SC-514

2442-5
EUR 131

SC-79

2766-1
EUR 131

SC-79

2766-5
EUR 251

5X RIPA Buffer

AKR-191 20mL
EUR 137
Description: RIPA Buffer extracts proteins from cultured mammalian cells for various downstream applications.

TBE Buffer, 5X

41006 4L
EUR 111
Description: Minimum order quantity: 1 unit of 4L

1L TBE 5X

NAT1200 1L
EUR 77

4L TBE 5X

NAT1202 4L
EUR 93

pGEX-5X-1

PVT0032 2 ug
EUR 266

pGEX- 5X- 2

PVT0033 2 ug
EUR 266

pGEX- 5X- 3

PVT0034 2 ug
EUR 266

5X TBE Buffer

T8051-100 2X500ml
EUR 82

5X TBE Buffer

T8051-200 4X500ml
EUR 107

5x Stop Buffer

TG4037 1ml
EUR 156

5X Potassium Glutamate

TG4055 1ml
EUR 156

MangoTaq Buffer 5x, Colourless

BIO-37101 10ml Ask for price

MangoTaq Buffer 5x, Coloured

BIO-37102 10ml Ask for price

RANGER Reaction Buffer, 5x

BIO-37114 3 x 1.25ml Ask for price

MyFi Reaction Buffer, 5x

BIO-37115 3 x 1.25ml Ask for price

5x TBE Buffer Solution

BA01805 6x100ml
EUR 94
Description: High purity buffer for various PCR applications.

5X Protein Loading Buffer

G031 3.0 ml
EUR 85

5X Passive Lysis Buffer

99912 30ML
EUR 77
Description: Minimum order quantity: 1 unit of 30ML

Protein Loading Buffer 5X

NAT1252 10X1ML
EUR 126

pGEX- 5X- 1 Plasmid

PVT0209 2 ug
EUR 241

pGEX- 5X- 2 Plasmid

PVT0210 2 ug
EUR 266

pGEX- 5X- 3 Plasmid

PVT0211 2 ug
EUR 266

Gyrase Assay Buffer 5x

TG4030 1ml
EUR 145

5X Band Sharpener (10ml)

9K-001-0017 10mL
EUR 323.76
  • Product category: PCR Related/Band Sharpener

Alkyne-PEG-SC

abx085263-10kDa1g 10 kDa; 1 g
EUR 801
  • Shipped within 5-10 working days.

Alkyne-PEG-SC

abx085263-20kDa1g 20 kDa; 1 g
EUR 801
  • Shipped within 5-10 working days.

Alkyne-PEG-SC

abx085263-2kDa1g 2 kDa; 1 g
EUR 801
  • Shipped within 5-10 working days.

Alkyne-PEG-SC

abx085263-5kDa1g 5 kDa; 1 g
EUR 801
  • Shipped within 5-10 working days.

MA-PEG-SC

abx085273-10kDa1g 10 kDa; 1 g
EUR 718
  • Shipped within 5-10 working days.

MA-PEG-SC

abx085273-20kDa1g 20 kDa; 1 g
EUR 718
  • Shipped within 5-10 working days.

Although there were no significant differences in quality of life among patients in 3 groups, overall patients who received reconstruction with flap reported better functioning and fewer symptoms. Those who did not receive any reconstruction reported the worse conditions.